Iovance Biotherapeutics (IOVA) Retained Earnings (2010 - 2026)

Iovance Biotherapeutics (IOVA) has reported Retained Earnings for 17 consecutive years, with $3.6 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Retained Earnings rose 9.24% year-over-year to $3.6 billion; the TTM figure through Mar 2026 stood at $3.6 billion (up 9.24% YoY), while the FY2025 annual figure was $3.5 billion, up 11.68% from the prior year.
• Retained Earnings climbed to $3.6 billion in Q1 2026 per IOVA's latest filing, from $3.5 billion in the prior quarter.
• Across five years, Retained Earnings topped out at $3.6 billion in Q1 2026 and bottomed at -$1.7 billion in Q1 2023.
• Historically, Retained Earnings has averaged $1.5 billion across 5 years, with a median of $2.6 billion in 2023.
• Annual changes were most pronounced in 2022 — Retained Earnings slumped 182.59% — and 2025, when it jumped 2812201.72%.
• Iovance Biotherapeutics' Retained Earnings stood at -$902000.0 in 2022, then surged by 287732.82% to $2.6 billion in 2023, then climbed by 19.33% to $3.1 billion in 2024, then advanced by 11.68% to $3.5 billion in 2025, then climbed by 3.07% to $3.6 billion in 2026.
• Business Quant data shows IOVA's Retained Earnings at $3.6 billion in Q1 2026, $3.5 billion in Q4 2025, and $3.4 billion in Q3 2025.